The Prognostic Value of the Chromobox Family in Human Ovarian Cancer

Xu, Yichi; Pan, Shuya; Song, Yizuo; Pan, Chunyu; Chen, Cheng; Zhu, Xueqiong

doi:10.7150/jca.44475

Cited by 20 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Chromobox (CBX) family consists of 8 members ranging from CBX1 to CBX8 in the human genome, with the common Polycomb Repressor Complex 1 (PCR1) in structure, an epigenetic regulatory complex that was intensively reported to regulate the epigenetic modification of chromatin and thereby take part in a variety of physiological (such as cell differentiation and DNA repair) and oncological processes (such as self-renewal of cancer stem cells). 6 , 7 The CBX family members can be further divided into two subgroups based on their protein structure: the heterochromatin protein 1 group (including CBX1, CBX3, and CBX5) and the polycomb group (including CBX2, CBX4, CBX6, CBX7, and CBX8). 8 Currently, increasing evidence demonstrated that CBX family members were involved in the initiation and progression of various cancers including but no limited to liver cancer, 9 lung cancer, 10 ovarian cancer, 11 and breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma

Hu¹,

Yao²,

Zhou³

et al. 2022

IJGM

View full text Add to dashboard Cite

Background The Chromobox (CBX) family members were involved in a variety of physiological and oncological processes through the regulation of the epigenetic modification of chromatin. However, the comprehensive analysis of the CBX family in head and neck squamous cell carcinoma (HNSC) is lacking. Methods In this work, we used multiple online databases and tools to investigate the roles of CBX family in aspects of gene expression, prognostic evaluation, genetic alteration, immune micro-environment of tumor, and status of methylation. Results The mRNA expression levels of CBX1, CBX3, and CBX5 were aberrantly increased in patients with HNSC, while CBX7 was aberrantly decreased. Higher expression of CBX7 was significantly associated with longer OS. Within the 5–11% of genetic alteration rate of CBXs, CBX3 ranked the highest and CBX5/7 ranked the lowest. SPRR1B, S100A7, CASP14, CDSN, LCE3D were the top 5 neighbor genes with the strongest association with CBXs in HNSC patients. Signaling pathways such as epidermal cell differentiation, cornification, and peptide cross-linking were demonstrated to have a strong association with CBX genes. The profiles of immune cell infiltration had high similarity for the group of HNSC patients stratified by expression of CBXs. The methylation levels of CBX1 and CBX5 significantly decreased, while that of CBX7 significantly increased in HNSC samples when compared with normal tissue. Conclusion In conclusion, the CBX family showed its valuation for further investigation in HNSC. Our research highlighted that CBX7 had the potential to be a novel diagnostic and prognostic biomarker for patients with HNSC.

show abstract

Section: Introductionmentioning

confidence: 99%

Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma

Hu¹,

Yao²,

Zhou³

et al. 2022

IJGM

View full text Add to dashboard Cite

show abstract

“…Ovarian carcinoma (OC), which can be divided into subtypes of epithelial ovarian carcinoma, germinoma, ovarian sex gonad stromal tumors, and metastatic tumors based on tissue origin, is one of the most lethal gynecologic tumors worldwide [ 1 ]. More than 220 thousand women are diagnosed with OC and 140 thousand die from it annually.…”

Section: Introductionmentioning

confidence: 99%

Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9

Kou

Ding

et al. 2021

Analytical Cellular Pathology

View full text Add to dashboard Cite

Purpose. Cisplatin is one of the most effective drugs for treating ovarian carcinoma (OC), which is among the most lethal types of carcinoma. However, the chemoresistance to cisplatin that develops over time leads to a poor clinical outcome for many OC patients. Therefore, it is necessary to clearly understand the molecular mechanisms of chemoresistance. In this study, we examined how Hsa-miR-105-1 functions in cisplatin-resistant OC cells. Methods. The levels of Hsa-miR-105-1 expression in cisplatin-sensitive and resistant OC cell lines were detected by qRT-PCR. The target gene of Hsa-miR-105-1 was predicted by using the TargetScan and Starbase databases and verified by the double luciferase reporter gene assay. The target gene of Hsa-miR-105-1 was identified as ANXA9, and ANXA9 expression was evaluated by qRT-PCR, western blotting, and immunofluorescence. To validate the function of Hsa-miR-105-1 in OC cells, we silenced or overexpressed Hsa-miR-105-1 in cisplatin-sensitive or resistant OC cell lines, respectively. Furthermore, the expression levels of several apoptosis-related proteins, including P53, P21, E2F1, Bcl-2, Bax, and caspase-3, were examined by western blot analysis. Results. The levels of Hsa-miR-105-1 expression were abnormally downregulated in cisplatin-resistant OC cells, while ANXA9 expression was significantly upregulated in those cells. Treatment with an Hsa-miR-105-1 inhibitor promoted the expression of ANXA9 mRNA and protein, enhanced the resistance to cisplatin, and attenuated the cell apoptosis induced by cisplatin in cisplatin-sensitive OC cells. Moreover, treatment with Hsa-miR-105-1 mimics inhibited ANXA9 expression, which further increased the levels of P53, P21, and Bax expression and decreased the levels of E2F1 and Bcl-2 expression, finally resulting in an increased sensitivity to cisplatin in cisplatin-resistant OC cells. Conclusion. We found that a downregulation of Hsa-miR-105-1 expression enhanced cisplatin-resistance, while an upregulation of Hsa-miR-105-1 restored the sensitivity of OC cells to cisplatin. The Hsa-miR-105-1/ANXA9 axis plays an important role in the cisplatin-resistance of OC cells.

show abstract

“…There is growing evidence that the CBX family of proteins plays vital roles in a variety of cancers. Abnormal expression levels of some members of the CBX family are associated with the prognosis of tumors, including breast, liver, and gastric tumors (12,13). It has also been shown that the CBX family is associated with tumour-infiltrating immune cells and may influence tumour progression and recurrence (14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

Prognostic and immune infiltrates for the Chromobox (CBX) protein family in human pancreatic adenocarcinoma

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

The Prognostic Value of the Chromobox Family in Human Ovarian Cancer

Cited by 20 publications

References 40 publications

Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma

Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma

Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9

Prognostic and immune infiltrates for the Chromobox (CBX) protein family in human pancreatic adenocarcinoma

Contact Info

Product

Resources

About